A recent clinical trial showed that a significant progression-free and overall survival benefit was associated with maintenance chemotherapy in patients with HER2-negative metastatic breast cancer who have disease control after six cycles of conventional chemotherapy. However, the choice of observation alone as the control arm limits the clinical application of these data.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Park, Y. H. et al. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2012.45.2490.
Alba, E. et al. Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer: GEICAM 2001–01 study. Breast Cancer Res. Treat. 122, 169–176 (2010).
Gennari, A. et al. Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J. Clin. Oncol. 24, 3912–3918 (2006).
National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)® Breast Cancer [online], (2013).
Bertelli, G. et al. Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer. Oncology 68, 364–370 (2005).
Dufresne, A. et al. Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer. Int. J. Med. Sci. 5, 100–105 (2008).
Seidman, A. D. The search for an elusive uniform strategy for a heterogeneous disease: lesson learned? J. Clin. Oncol. http://dx.doi.org/10.1200/JCO.2013.48.6894.
Broglio, K. B. & Berry, D. A. Detecting an overall survival benefit that is derived from progression-free survival. J. Natl Cancer Inst. 101, 1642–1649 (2009).
OShaughnessy, J. et al. A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC) [abstract]. J. Clin. Oncol. 28 (Suppl. 15), a1005 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Martín, M., López-Tarruella, S. Maintenance therapy in breast cancer—many questions remain. Nat Rev Clin Oncol 10, 370–372 (2013). https://doi.org/10.1038/nrclinonc.2013.87
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2013.87
This article is cited by
-
Complete remission in metastatic breast cancer: expecting the unexpected—results of a cross-sectional study
Breast Cancer (2017)
-
The role of maintenance strategies in breast cancer
memo - Magazine of European Medical Oncology (2014)